Filing Details
- Accession Number:
- 0000899243-16-019823
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-05-13 06:15:19
- Reporting Period:
- 2016-05-11
- Filing Date:
- 2016-05-13
- Accepted Time:
- 2016-05-13 06:15:19
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1652130 | Intellia Therapeutics Inc. | NTLA | () | 0331 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1021944 | Ltd (Private) Holdings Temasek | 60B Orchard Road #06-18 Tower 2 The Atrium@Orchard Singapore U0 238891 | No | No | Yes | No | |
| 1379348 | Ltd Pte Management Fullerton | 60B Orchard Road #06-18 Tower 2 The Atrium@Orchard Singapore U0 238891 | No | No | Yes | No | |
| 1379349 | Ltd Private Sciences Life Temasek | 60B Orchard Road #06-18 Tower 2 The Atrium@Orchard Singapore U0 238891 | No | No | Yes | No | |
| 1673754 | Ltd. Pte. Beta Tls | 60B Orchard Road #06-18 Tower 2 The Atrium@Orchard Singapore U0 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2016-05-11 | 490,527 | $0.00 | 490,527 | No | 4 | C | Indirect | Held by TLS Beta Pte. Ltd. |
| Common Stock | Acquisiton | 2016-05-11 | 300,000 | $18.00 | 790,527 | No | 4 | P | Indirect | See footnote |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | Held by TLS Beta Pte. Ltd. |
| No | 4 | P | Indirect | See footnote |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series B Preferred Stock | Disposition | 2016-05-11 | 490,527 | $0.00 | 490,527 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect |
Footnotes
- In connection with the closing of the Issuer's initial public offering of Common Stock on May 11, 2016, each share of Series B Preferred Stock automatically converted into 0.6465903 of a share of Common Stock without payment or further consideration.
- TLS Beta Pte. Ltd. is a wholly-owned subsidiary of Temasek Life Sciences Private Limited, which in turn is a wholly-owned subsidiary of Fullerton Management Pte Ltd, which in turn is a wholly-owned subsidiary of Temasek Holdings (Private) Limited. Accordingly, each of Temasek Life Sciences Private Limited, Fullerton Management Pte Ltd and Temasek Holdings (Private) Limited, through the ownership described herein, may be deemed to beneficially own the shares of Common Stock owned by TLS Beta Pte. Ltd.
- Includes 490,527 shares held by TLS Beta Pte. Ltd. and 300,000 shares held by Evans Investments Pte. Ltd. Evans Investments Pte. Ltd. is a wholly-owned subsidiary of Temasek Capital (Private) Limited, which in turn is a wholly-owned subsidiary of Temasek Holdings (Private) Limited. Accordingly, Temasek Holdings (Private) Limited, through the ownership described herein, may be deemed to beneficially own the shares of Common Stock owned by TLS Beta Pte. Ltd. and Evans Investments Pte. Ltd.
- None.
Billionaire Hedge Funds
